Upstream Bio Inc. (UPB)
NASDAQ: UPBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
UPB stock chart
Technical analysisKey statistics
All statistics- Market cap
- $87.15M
- EPS (TTM)
- -$3.01
- Dividend yield
- None
- 52-week range
- 1.56 – 33.68
- Day range
- 1.56 – 2.06
- Volume / Avg
- 1.39M / 1.01M
- Beta
- —
- Shares outstanding
- 54.81M
52-week range
UPB stock today
Upstream Bio (UPB) closed at $1.59 on Nov 20, down 20.50% (-$0.41), versus the S&P 500's 3.70% decline. Shares are 95.3% below their 52-week high of $33.68, set on Jan 14, 2026 and 1.9% above the 52-week low of $1.56, near the bottom of the past year's range. UPB is down 94.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 93.8%.
Upstream Bio has posted a net loss over the last twelve months (EPS of -$3.01), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Upstream Bio
Company profileUpstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. E. Rand Sutherland M.D., M.P.H.
- Headquarters
- Waltham, MA
- Employees
- 75
- IPO year
- 2024
- Website
- upstreambio.com
Financial highlights
Full financialsIn fiscal 2025, Upstream Bio generated $2.9 million in revenue, up 20.4% from fiscal 2024. Upstream Bio reported a net loss of $143.4 million, compared with a loss of $62.8 million a year earlier. Operating margin was -5618.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $2.85M | $2.37M | $2.38M |
| Growth | +20.42% | -0.42% | — |
| Net income | $-143.44M | $-62.81M | $-20.54M |
| EPS (diluted) | $-2.66 | $-5.58 | $-12.95 |
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$21.40+1245.91%
- Strong buy 1
- Buy 4
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.75 vs $-0.67
- Surprise
- -11.94%
UPB news
All UPB newsUpstream Bio peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EQEquillium Inc. | 1.06 | -5.36% | $87.26M | vs UPB |
| RTSNRetension Pharmaceuticals Inc. | 10.51 | -19.22% | $87.57M | vs UPB |
| CPIXCumberland Pharmaceuticals Inc. | 5.84 | -7.30% | $87.57M | vs UPB |
| ANIXAnixa Biosciences Inc. | 2.44 | -6.15% | $84.82M | vs UPB |
| NTHINeOnc Technologies Holdings Inc. | 3.15 | -9.48% | $90.88M | vs UPB |
| CATXPerspective Therapeutics Inc. | 0.7538 | -3.85% | $91.03M | vs UPB |
| OGIOrganigram Global Inc. | 0.583 | -7.40% | $82.27M | vs UPB |
| HURATuHURA Biosciences Inc. | 1.25 | -8.09% | $82.20M | vs UPB |
Indexes, lists and sector
Upstream Bio stock FAQ
What is Upstream Bio's stock price today?
UPB last traded at $1.59 as of Nov 20, 4:00 PM EST, down 20.50% on the day. Prices are delayed at least 15 minutes.
Who is Upstream Bio's CEO?
Dr. E. Rand Sutherland M.D., M.P.H. is the chief executive officer of Upstream Bio Inc., which has about 75 employees.
What is the UPB 52-week high?
The 52-week high for UPB is $33.68 and the 52-week low is $1.56. The stock is currently 95.3% below its high.